IPOs get back in­to gear with fil­ings from Lian­Bio and Xilio, and Cor­moran­t's SPAC has a deal

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

As the fourth quar­ter gets un­der­way, the biotech IPO mar­ket is revving its en­gines back up.

Two more com­pa­nies filed to make their Nas­daq de­buts Fri­day, Xilio Ther­a­peu­tics and Lian­Bio, each pen­cil­ing in the stan­dard $100 mil­lion es­ti­mate. There was al­so a SPAC merg­er that land­ed ear­ly Mon­day morn­ing, as a blank check com­pa­ny from Cor­morant As­set Man­age­ment re­verse merged with Swiss biotech Moon­Lake Im­munother­a­peu­tics in a $230 mil­lion deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.